Which criterion excludes a patient from fibrinolysis therapy in the setting of ischemic stroke?

Study for the Board Certified Cardiology Pharmacist Exam. Utilize flashcards and answer multiple-choice questions with detailed explanations. Prepare efficiently for your certification!

Uncontrolled hypertension is a significant contraindication for fibrinolysis therapy in patients experiencing an ischemic stroke. The primary concern is that elevated blood pressure can increase the risk of hemorrhagic transformation, a severe complication that can occur when tissue plasminogen activator (tPA) is administered. When fibrinolytic therapy is given, it aims to dissolve the clot and restore blood flow, but if the blood pressure is excessively high, it can lead to bleeding in the brain.

Management protocols typically recommend that blood pressure be controlled to a certain threshold before starting fibrinolysis. The threshold often cited is that blood pressure should be less than 185/110 mmHg in patients eligible for this therapy. If a patient's blood pressure exceeds this level, it would exclude them from being candidates for fibrinolytic therapy, due to the heightened risk associated with their hypertensive state.

While other options such as time from symptom onset, recent arterial puncture, and aspirin use can also influence decisions regarding fibrinolysis, uncontrolled hypertension stands out as a direct and critical exclusionary criterion due to safety concerns regarding potential complications.

Subscribe

Get the latest from Examzify

You can unsubscribe at any time. Read our privacy policy